Applied Health Research Group
Aston Research Centre for Healthy Ageing (ARCHA)
Aston Research centre in CHildren and Young people's health(ARCHY)
Although only starting my current role as lecturer in pharmaceutics in 2010, I have a long history with Aston University.
First of all, I studied here for a BSc in Combined Honours Chemistry and French, graduating in 2004, part of which involved a sandwich year in a university research laboratory in Montpellier, France.
I then studied for a PhD on the subject of formulation and characterisation of particulate delivery systems for TB vaccines, again at Aston University, under the supervision of Prof. Yvonne Perrie.
Before taking up my current role, I was an Aston based post-doc, acting as Formulation Research Fellow for the UK Medicines for Children Research Network.
PH1403: Basic maths, graphical methods, formulation calculations, statisticsPH1404: Routes of delivery, suspensions, emulsions, creams and ointments, liquid filled gel capsulesPH4701: Paediatric drug delivery, microspheres, ocular drug delivery
Based within the pharmaceutics laboratories of Aston Pharmacy School, my main area of research is the formulation of age-appropriate medicines for the extremes of life - paediatric and geriatric populations - with a focus on the identification of priorities for further research in older, established medicines, as well as the use of polymer based systems and alternative dosage forms to improve acceptability and practicality of medicines by, for example, extending stability and providing taste-masking.
A particular area of interest is that of extemporaneous formulation – that is the process of compounding ingredients to prepare a medicine for an individual patient when no commercial forms are available – which is extremely prevalent for the paediatric and geriatric population, due to a severe lack of age-appropriate dosage forms available on the market. In an attempt to tackle the major issues, our research involves engagement with representative groups of patients, carers and prescribers, whilst robust pharmaceutical characterisation of problematic formulations requiring investigation will also be performed, as well as development of novel dosage forms. This is being conducted in order to both inform current practice and strive towards improved, age-appropriate formulations. Current projects include the development of orally dissolving films and orally disintegrating tablets for paedatric applications, polymer based taste-masking platform technologies and novel uses of liposomes and carbon based systems for improved drug delivery.
Self-funded PhD projects in Pharmaceutics / Drug Delivery will be available shortly for prospective students. It is envisaged that fully funded studentships will also become available.
Al-Khattawi, A., Koner, J., Rue, P., Kirby, D., Perrie, Y., Rajabi-Siahboomi, A. and Mohammed, A. R. (2015) A pragmatic approach for engineering porous mannitol and mechanistic evaluation of particle performance. European Journal of Pharmaceutics and Biopharmaceutics, 94(0), 1-10.
Koner, J.S., Rajabi-Siahboomi, A., Bowen, J., Perrie, Y., Kirby, D., Mohammed, A. R. (submitted) A Holistic Multi Evidence Approach to Study the Fragmentation Behaviour of Crystalline Mannitol.
Kirby, D.J.,Kaur, R., Agger, E.M., Andersen, P., Bramwell, V.W. & Perrie, Y. (2013) Developing solid particulate vaccine adjuvants - surface bound antigen favouring a humoural response, whereas entrapped antigen shows a tendency for cell mediated immunity. Current drug delivery 11(6), 268-278. 10.2174/1567201811310030003
Perrie Y, Badhan R.K., Kirby D.J., Lowry D, Mohammed A.R., Ouyang D. (2012) The impact of ageing on the barrier to drug delivery. J Control Release161(2):389-398.
Wilkhu, J., McNeil, S.E., Kirby, D.J., Perrie, Y. (2011) Formulation design considerations for oral vaccines. Therapeutic Delivery 2(9):1141-1164